No More Technicians in the Shadows: Bringing Interventional Oncology into the Light of Multidisciplinary Tumor Boards

2021 ◽  
Author(s):  
Julien Garnon
Keyword(s):  
Interventional Oncology ◽  
Tumor Boards

Virtual Clinical and Precision Medicine Tumor Boards: A Cloud-based Platform-mediated Implementation of Multidisciplinary Reviews among Oncology Centers in the Covid-19 Era. (Preprint)

2020 ◽  
Author(s):  
Livio Blasi ◽  
Roberto Bordonaro ◽  
Vincenzo Serretta ◽  
Dario Piazza ◽  
Alberto Firenze ◽  
...  
Keyword(s):  
Decision Making ◽  
Health Professionals ◽  
Clinical Pathways ◽  
Prospective Trial ◽  
Banking System ◽  
Outcome Data ◽  
Tumor Board ◽  
Time Saving ◽  
Tumor Boards ◽  
Multidisciplinary Tumor Board

BACKGROUND Multidisciplinary tumor boards play a pivotal role in the patients -centered clinical management and in the decision-making process to provide best evidence -based, diagnostic and therapeutic care to cancer patients. Among the barriers to achieve an efficient multidisciplinary tumor board, lack of time and geographical distance play a major role. Therefore the elaboration of an efficient virtual multidisciplinary tumor board (VMTB) is a key-point to reach a successful oncology team and implement a network among health professionals and institutions. This need is stronger than ever in a Covid-19 pandemic scenario. OBJECTIVE This paper presents a research protocol for an observational study focused on exploring the structuring process and the implementation of a multi-institutional VMTB in Sicily. Other endpoints include analysis of cooperation between participants, adherence to guidelines, patients’ outcomes, and patients satisfaction METHODS This protocol encompasses a pragmatic, observational, multicenter, non-interventional, prospective trial. The study's programmed duration is five years, with a half-yearly analysis of the primary and secondary objectives' measurements. Oncology care health-professionals from various oncology subspecialties at oncology departments in multiple hospitals (academic and general hospitals as well as tertiary centers and community hospitals) are involved in a non-hierarchic fashion. VMTB employ an innovative, virtual, cloud-based platform to share anonymized medical data which are discussed via a videoconferencing system both satisfying security criteria and HIPAA compliance. RESULTS The protocol is part of a larger research project on communication and multidisciplinary collaboration in oncology units and departments spread in the Sicily region in Italy. Results of this study will particularly focus on the organization of VMTB involving oncology units present in different hospitals spread in the area and create a network to allow best patients care pathways and a hub and spoke relationship. Results will also include data concerning organization skills and pitfalls, barriers, efficiency, number and type con clinical cases, and customers’ satisfaction. CONCLUSIONS VMTB represents a unique opportunity to optimize patient’s management in a patient centered approach. An efficient virtualization and data banking system is potentially time-saving, a source for outcome data, and a detector of possible holes in the hull of clinical pathways. The observations and results from this VMTB study may hopefully useful to design nonclinical and organizational interventions that enhance multidisciplinary decision-making in oncology.

scholarly journals Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members

2021 ◽  
Author(s):  
Shannon Fortin Ensign ◽  
Maya Hrachova ◽  
Susan Chang ◽  
Maciej M Mrugala
Keyword(s):  
Online Survey ◽  
Clinical Decision Making ◽  
Unmet Needs ◽  
Practice Patterns ◽  
Response Rate ◽  
Clinical Decision ◽  
Molecular Testing ◽  
Newly Diagnosed ◽  
Tumor Boards ◽  
Oncology Practice

Abstract Background Molecular testing (MT) is utilized in neuro-oncology with increasing frequency. The aim of this study was to determine clinical practice patterns to acquire this information, interpret and utilize MT for patient care, and identify unmet needs in the practical clinical application of MT. Methods We conducted a voluntary online survey of providers within the Society for Neuro-Oncology (SNO) membership database between March and April 2019. Results We received 152 responses out of 2022 SNO members (7.5% of membership). 88.8% of respondents routinely order MT for newly diagnosed gliomas. Of those who do not, testing is preferentially performed in younger patients or those with midline tumors. 82.8% use MT in recurrent gliomas. Other common indications included: metastatic tumors, meningioma, and medulloblastoma. Many providers utilize more than one resource (36.0%), most frequently using in-house (41.8%) over commercially available panels. 78.1% used the results for clinical decision-making, with BRAF, EGFR, ALK, and H3K27 mutations most commonly directing treatment decisions. Approximately, half (48.5%) of respondents have molecular tumor boards at their institutions. Respondents would like to see SNO-endorsed guidelines on MT, organized lists of targeted agents available for specific mutations, a database of targetable mutations and clinical trials, and more educational programs on MT. Conclusion This survey was marked by several limitations including response rate and interpretation of MT. Among respondents, there is routine use of MT in Neuro-Oncology, however, there remains a need for increased guidance for providers to effectively incorporate the expanding genomic data resulting from MT into daily Neuro-Oncology practice.

scholarly journals Interventional Oncology Approach to Hepatic Metastases

2020 ◽  
Vol 37 (05) ◽  
pp. 484-491
Author(s):  
Cathal O'Leary ◽  
Michael C. Soulen ◽  
Susan Shamimi-Noori
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Interventional Oncology ◽  
Hepatic Metastases ◽  
Locoregional Therapy ◽  
Treatment Modalities ◽  
Patient Specific ◽  
Curative Intent ◽  
Locoregional Therapies ◽  
Metastatic Liver

AbstractMetastatic liver disease is one of the major causes of cancer-related morbidity and mortality. Locoregional therapies offered by interventional oncologists alleviate cancer-related morbidity and in some cases improve survival. Locoregional therapies are often palliative in nature but occasionally can be used with curative intent. This review will discuss important factors to consider prior to palliative and curative intent treatment of metastatic liver disease with locoregional therapy. These factors include those specific to the tumor, liver function, liver reserve, differences between treatment modalities, and patient-specific considerations.

Radiogenomics in Interventional Oncology

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Amgad M. Moussa ◽  
Etay Ziv
Keyword(s):  
Interventional Oncology

scholarly journals Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards

ESMO Open ◽  
2021 ◽  
Vol 6 (2) ◽  
pp. 100040 ◽  
Author(s):  
R. Danesi ◽  
S. Fogli ◽  
S. Indraccolo ◽  
M. Del Re ◽  
A.P. Dei Tos ◽  
...  
Keyword(s):  
Tumor Boards ◽  
Classification Of Tumors ◽  
Druggable Targets

PO-0260 INTERBOARD: a dedicated tumor board to deal with personalized medicine in interventional oncology.

2021 ◽  
Vol 158 ◽  
pp. S213-S214
Author(s):  
C. Casà ◽  
R. Iezzi ◽  
F. Bruno ◽  
P. Cornacchione ◽  
M. Iezzi ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Interventional Oncology ◽  
Tumor Board

Virtual Molecular Tumor Boards

2017 ◽  
Vol 32 (5) ◽  
pp. 46-52
Keyword(s):  
Tumor Boards

Future Interventional Oncology Catheter-Based Therapies

2017 ◽  
Vol 01 (03) ◽  
pp. 225-232
Author(s):  
Christopher Noda ◽  
Mihail Roubhaka ◽  
Resmi Charalel ◽  
Abdulrahman Masrani ◽  
Olaguoke Akinwande
Keyword(s):  
Minimally Invasive ◽  
Interventional Oncology ◽  
Complete Removal ◽  
Systemic Delivery ◽  
Delivery Method ◽  
Viral Therapy ◽  
Attractive Option ◽  
Rapid Pace ◽  
Invasive Techniques ◽  
All Diseases

AbstractMinimally invasive techniques in the treatment of cancer continue to develop at a rapid pace. Although surgical resection currently remains the only option for a complete cure, not all diseases are amenable to complete removal. This leaves opportunities to develop effective downstaging techniques as well as palliative care. In the realm of minimally invasive oncologic techniques, catheter-based therapies are an attractive option because malignancies require a blood supply to remain active. The intra-arterial (IA) delivery of specific tumoricidal drugs has been shown to be a successful delivery method in a variety of different cancers, and it is currently a progressive area of research. There is work both to increase the delivery specificity of oncologic drugs, including SW43 sigma receptor ligand and nanoparticle research. In addition, oncolytic viral therapy and 3-bromopyruvate have become increasingly more attractive tumoricidal drug prospects. In the future, the success of these therapies will ultimately determine the degree to which IA delivery will compete with the systemic delivery of drugs in the treatment of cancer.

Sign in / Sign up

Export Citation Format

Share Document